Podcast appearances and mentions of Johnson Johnson

In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including:CLL17: randomized phase III trial of continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for untreatedCLL BRUIN CLL-313: randomized phase III trial of pirtobrutinib vs BR for previously untreated patients with CLLBRUIN CLL-314: pirtobrutinib vs ibrutinib in treatment-naive and BTKi-naive R/R CLL/SLL EPCORE-FL-1: randomized phase III trial of epcoritamab with rituximab and lenalidomide vs rituximab and lenalidomide for R/R FLSTARGLO: 3-year follow-up data from the randomized phase III trial of glofitamab plus GemOx vs rituximab plus GemOx for patients with R/R DLBCLPresenter: Jeremy S. Abramson, MD, MMScProfessor of MedicineHarvard Medical SchoolDirector, Center for LymphomaMass General Brigham Cancer InsBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/4aqMobZ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Patrick Ropella is the Founder and Chairman of Ropella 360, a global executive search and advisory firm specializing in connecting transformational leaders with private equity and mid-market companies. With over 35 years of experience, he has contributed to the growth of major global corporations such as Dow, General Electric, BASF, Nike, and Johnson & Johnson. As the author of The Right Hire and Pathways to Private Equity Partnerships, Patrick's C-suite and investor insights are featured in hundreds of publications worldwide. His strategic vision and expertise have made him a trusted advisor to leaders across industries. In this episode… The path to extraordinary success often starts in unexpected places — from humble beginnings to high-stakes boardrooms. Some people manage to rise without the usual credentials, building influence, trust, and transformative relationships along the way. What enables someone to become a connector who impacts leaders, industries, and entire organizations? According to Patrick Ropella, a renowned leadership strategist, the real advantage comes from mastering human connection rather than relying on traditional qualifications. He highlights how deep listening, specialization, and long-term trust outperform transactional sales and recruiting. This approach creates lasting impact by aligning the right leaders with the right missions. Over decades, he developed a system for identifying A-players, ensuring cultural fit, and supporting leadership transformation across complex industries. His stories — from helping global brands innovate to supporting frontier-technology teams — show how clarity, accountability, and relationship-building shape high-performance outcomes. In this episode of the Inspired Insider Podcast, Dr. Jeremy Weisz sits down with Patrick Ropella, Founder and Chairman of Ropella 360, to discuss building elite teams through authentic leadership. They explore how to identify A-players, the principles behind his Smart Search System, and what drives lasting transformation in organizations. Patrick also shares insights on trust, communication, and scaling through strong relationships.

In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including: LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatmentAbstract 844: Secondary analysis results from VAYHIT3, a phase II study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least 2 lines of therapyAbstract 5: Deciphering the dilemma: intravenous (IV) iron use in iron deficiency anemia during acute infectionsAbstract 308: Subcutaneous, every-4-week maintenance dosing of a novel protein S antibody is well tolerated and substantially reduces bleeding rates: results from a phase I/II multidose study of VGA039 in patients with von Willebrand diseaseAbstract 841: Immune thrombocytopenia in patients treated with immune checkpoint inhibitorsPresenter:Hanny Al-Samkari, MDThe Peggy S. Blitz Endowed Chair in Hematology/OncologyCo-Director, Hereditary Hemorrhagic Telangiectasia Center of ExcellenceMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hear from Dr. Adam Friedman, MD, FAAD, professor and chair of Dermatology at The George Washington University School of Medicine & Health Sciences, discuss the innovative teledermatology psoriasis clinic held at The Pennsylvania Avenue Baptist Church. He is joined by Reverends Kendrick, Ph.D., and Karen Curry, as they discuss why they've opened their church to this program and how they have made this relationship work.  This episode is sponsored by Johnson & Johnson.

In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AMLAbstract 47: Phase I/II SAVE trial of revumenib plus decitabine/cedazuridine and venetoclax in the cohort of patients with newly diagnosed AMLAbstract 766: Phase Ib KOMET-007 trial of ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-mutant AMLAbstract 654: Phase I/II VICEROY trial of venetoclax and azacitidine + gilteritinib in patients with newly diagnosed FLT3-mutated AML ineligible for intensive induction chemotherapyAbstract 903: 3-Yr Update of the phase II FASCINATION trial of asciminib and conventional BCR::ABL1 inhibitors in newly diagnosed CMLAbstract 906: Phase II ASC2ESCALATE trial of asciminib in patients with chronic-phase CML after 1 prior TKIPresenter:Amir T. Fathi, MDDirector, Leukemia ProgramMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

About Beth McCombs:Elizabeth “Beth” McCombs is the executive vice president and chief technology officer of BD, where she leads the company's global research and development organization. She oversees the full spectrum of innovation—from early-stage concept development to product launch—and ensures the continued advancement of BD's existing portfolio. As a member of the BD Executive Leadership Team, she plays a central role in shaping the company's long-term technology and growth strategy. Beth joined BD in 2019 as Senior Vice President of R&D for the BD Medical segment, co-leading portfolio strategy and major growth initiatives. Before joining BD, she spent over two decades at Johnson & Johnson, including serving as Vice President of R&D for Ethicon, the company's surgical devices franchise. She holds both a B.S. and an M.S. in mechanical engineering from the Massachusetts Institute of Technology and an MBA from the Wharton School of the University of Pennsylvania.Things You'll Learn:BD approaches innovation by deeply studying clinical workflows and ensuring new technologies solve meaningful, scalable problems. Real-world evidence and clinical validation are built into the process from the start.Connected medication management solutions can eliminate waste, prevent errors, and free up clinical resources. Tracking drugs from the central pharmacy to the bedside improves safety and system-level efficiency.Vascular access improvements achieved through product design and standardized training dramatically reduced cost, blood exposure, and catheter failure rates. This proves that outcomes hinge on combining the right device with the right practices.AI and machine-learning capabilities, such as predicting hypotension during cardiac surgery, aim to reduce complications, costs, and length of stay. These tools evolve by partnering with health systems to measure real-world impact.BD Incada represents a shift to cloud-based, interoperable, AI-enabled infrastructure that unifies data across entire health systems. This foundation accelerates the future of personalized care and integrated device ecosystems.Resources:Connect with and follow Beth McCombs on LinkedIn.Follow BD on LinkedIn  and visit their website.

This Day in Legal History: Bill of Rights RatifiedOn December 15, 1791, the Bill of Rights was officially ratified, marking a foundational moment in American legal history. With Virginia becoming the crucial eleventh state to approve the measure, the first ten amendments to the U.S. Constitution achieved the three-fourths majority required for adoption. These amendments were crafted in response to fears that the newly formed federal government might trample on individual freedoms, a concern strongly voiced by the Anti-Federalists during the Constitution's ratification debates. Drafted primarily by James Madison, the Bill of Rights was intended to secure essential civil liberties and limit government power.The amendments enshrine core protections such as freedom of speech, religion, and the press, the right to bear arms, and safeguards against unreasonable searches and seizures. They also provide important rights to those accused of crimes, including the right to a fair trial, protection against self-incrimination, and freedom from cruel and unusual punishment. At the time, these provisions applied only to the federal government, but their scope was later expanded through the Incorporation Doctrine using the Fourteenth Amendment.The ratification of the Bill of Rights represented a political compromise but ultimately became a defining element of American constitutional identity. Over the centuries, courts have invoked these amendments in countless rulings, from free speech cases to gun rights and due process protections. The Bill of Rights not only shapes modern legal debates but also remains a symbol of the nation's enduring commitment to individual liberty and the rule of law. Its ratification on this day in 1791 continues to influence how justice is understood and delivered in the United States.Judge Hannah Dugan of the Milwaukee County Circuit Court is on trial for allegedly obstructing an immigration arrest in her courtroom, a case seen as a test of Donald Trump's aggressive immigration enforcement policies. Federal prosecutors accuse Dugan of helping a Mexican migrant, Eduardo Flores-Ruiz, evade arrest by redirecting ICE agents and escorting the defendant through a non-public exit after his hearing. Dugan, who has been suspended from the bench, has pleaded not guilty to charges of concealing a person from arrest and obstructing federal proceedings.Prosecutors claim she acted corruptly and misled law enforcement, allegedly showing anger when she learned of ICE's presence and insisting a judicial warrant was needed. Dugan's defense argues she acted in good faith, following courthouse policy designed to handle ICE encounters after previous controversial arrests. The trial highlights growing legal and political tensions around courthouse arrests, which critics say intimidate immigrants and undermine trust in the legal system. The outcome could influence how far judges and local officials can go in pushing back against federal immigration actions.Wisconsin judge faces trial for stopping courtroom arrest of migrant in Trump crackdown | ReutersCalifornia filed a lawsuit against the Trump administration for cutting over $33 million in federal grants intended for commercial vehicle safety programs. The U.S. Department of Transportation, led by Secretary Sean Duffy, justified the funding termination by claiming California failed to properly enforce English proficiency requirements for truck drivers. California argues its standards align with federal rules and called the decision unlawful and harmful to public safety and the economy.The lawsuit comes amid broader efforts by the Trump administration to crack down on non-English-speaking and non-U.S. citizen truck drivers. This includes halting commercial driver visas and threatening similar funding cuts in states like New York and Minnesota. The administration has also targeted Democrat-led states for other transportation-related penalties. In California's case, the withheld funds were designated for safety inspections, audits, traffic enforcement, and education programs.California contends that its licensed drivers are involved in significantly fewer fatal crashes than the national average, challenging the administration's justification. The legal dispute reflects escalating tensions between federal agencies and Democratic states over immigration and transportation enforcement.California sues Trump administration over terminated transportation grants | ReutersA federal judge ruled that evidence seized from Daniel Richman, a former attorney for ex-FBI Director James Comey, was wrongfully retained by prosecutors, presenting a hurdle for any new charges against Comey. U.S. District Judge Colleen Kollar-Kotelly ordered the Department of Justice to return the files but allowed a sealed copy to remain with the court should prosecutors later obtain a valid warrant. Richman had filed a lawsuit claiming the DOJ had improperly held onto materials seized during an investigation that ended in 2021 without charges.While the judge found the DOJ's actions amounted to an unreasonable seizure, she declined to prevent the department from pursuing future leads based on the information already reviewed. The seized files had been used earlier this year to support an indictment against Comey, accusing him of making false statements and obstructing Congress over his 2020 testimony.That indictment, along with one against New York Attorney General Letitia James, was dismissed last month after it was found the prosecutor involved had been unlawfully appointed. The judge's ruling now complicates the DOJ's ability to revive its case against Comey, a frequent critic of Donald Trump and a central figure in past investigations into Trump's conduct.Judge says Comey evidence was wrongfully retained, creating hurdle for new charges | ReutersA California jury has ordered Johnson & Johnson to pay $40 million to two women who claimed its talc-based baby powder caused their ovarian cancer. The jury awarded $18 million to Monica Kent and $22 million to Deborah Schultz and her husband, finding the company failed to warn consumers despite allegedly knowing of the product's risks for decades. Both women testified that they used the powder for over 40 years and have undergone extensive cancer treatments since their diagnoses in 2014 and 2018.J&J denies the product causes cancer and plans to appeal the verdict, calling it an “aberrant” outcome. The company points out that no major U.S. health agency has definitively linked talc to ovarian cancer and argues that plaintiffs' claims rely solely on legal arguments rather than scientific consensus.This is the first talc trial to move forward since J&J's latest bankruptcy attempt, aimed at resolving over 67,000 similar lawsuits, was rejected by the courts. The company previously stopped selling talc-based baby powder in the U.S. in 2020. While it has faced some large verdicts—including a $4.69 billion award in a past case—it has also won dismissals and reductions on appeal. In addition to ovarian cancer claims, J&J is also facing suits linking its talc products to mesothelioma, with some recent verdicts exceeding $900 million.Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RMT865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 25, 2026.Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RMT865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 25, 2026.Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RMT865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 25, 2026.Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RMT865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 25, 2026.Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

On this Live Greatly podcast episode, Kristel Bauer sits down with "Courage Catalyst" Dr. Margie Warrell, six-time bestselling author of The Courage Gap.  Kristel and Margie discuss how to navigate being an insecure overachiever and how to build courage. Tune in now!  Key Takeaways From This Episode: A look into being an insecure overachiever and how to overcome it Tips to build courage within ourselves A look into Dr. Warrell's book, The Courage Gap ABOUT DR. MARGIE WARRELL Dr. Margie Warrell is a six-time bestselling author, leadership advisor, keynote speaker, and "courage catalyst" bringing deep insight into human and organizational behavior to foster braver leadership and better outcomes.  Dr. Warrell has gained profound insights on managing fear, navigating risk, and embracing change since her childhood in rural Australia. Thirty years of living and working around the world—from Papua, New Guinea to Singapore—have provided her with a globally grounded perspective on navigating risk and overcoming the barriers that stifle potential in individuals and organizations. Drawing on her doctoral research and experience in coaching and Fortune 500 consulting, Dr. Warrell is a trusted advisor across private and public sectors, helping to embolden braver leadership and cultivate forward-thinking "cultures of courage" that counter change resistance, foster learning, and accelerate growth. Organizations such as NASA, Dell, Morgan Stanley, SAP, Novartis, the UN Foundation, HP, Google, and Johnson & Johnson have sought her expertise.  Author of the new book, The Courage Gap, Dr. Warrell is renowned for her ability to bridge the "head and heart" as a writer and speaker. She has also co-authored two other books with Stephen Covey, Ken Blanchard, and Jack Canfield. Her interviews with leaders and luminaries—including Bill Marriott, Richard Branson, and Amy Edmondson of Harvard Business School—inform her thought leadership, which she shares through her global top 1.5% podcast, Live Brave, Forbes column, and leading media outlets such as CNN, Bloomberg, and the WSJ. Dr. Warrell's commitment to "braver leadership for a better world" extends to advising US Congressional Chiefs, McCain Global Fellows, and emerging female leaders in burgeoning democracies. A passionate advocate for women in leadership, she has served on numerous government roundtables, co-led Korn Ferry's Power of All initiative to advance more women to C-suite and board tables, and been Senior Partner in their CEO & Leadership Institute. Connect with Dr. Warrell Order Dr. Warrell's book: https://a.co/d/81cuf2F  Website: https://margiewarrell.com/  Linkedin: https://www.linkedin.com/in/margiewarrell/  Instagram: https://www.instagram.com/margiewarrell/  About the Host of the Live Greatly podcast, Kristel Bauer: Kristel Bauer is a corporate wellness and performance expert, keynote speaker and TEDx speaker supporting organizations and individuals on their journeys for more happiness and success. She is the author of Work-Life Tango: Finding Happiness, Harmony, and Peak Performance Wherever You Work (John Murray Business November 19, 2024). With Kristel's healthcare background, she provides data driven actionable strategies to leverage happiness and high-power habits to drive growth mindsets, peak performance, profitability, well-being and a culture of excellence. Kristel's keynotes provide insights to "Live Greatly" while promoting leadership development and team building.   Kristel is the creator and host of her global top self-improvement podcast, Live Greatly. She is a contributing writer for Entrepreneur, and she is an influencer in the business and wellness space having been recognized as a Top 10 Social Media Influencer of 2021 in Forbes. As an Integrative Medicine Fellow & Physician Assistant having practiced clinically in Integrative Psychiatry, Kristel has a unique perspective into attaining a mindset for more happiness and success. Kristel has presented to groups from the American Gas Association, Bank of America, bp, Commercial Metals Company, General Mills, Northwestern University, Santander Bank and many more. Kristel has been featured in Forbes, Forest & Bluff Magazine, Authority Magazine & Podcast Magazine and she has appeared on ABC 7 Chicago, WGN Daytime Chicago, Fox 4's WDAF-TV's Great Day KC, and Ticker News. Kristel lives in the Fort Lauderdale, Florida area and she can be booked for speaking engagements worldwide. To Book Kristel as a speaker for your next event, click here. Website: www.livegreatly.co  Follow Kristel Bauer on: Instagram: @livegreatly_co  LinkedIn: Kristel Bauer Twitter: @livegreatly_co Facebook: @livegreatly.co Youtube: Live Greatly, Kristel Bauer To Watch Kristel Bauer's TEDx talk of Redefining Work/Life Balance in a COVID-19 World click here. Click HERE to check out Kristel's corporate wellness and leadership blog Click HERE to check out Kristel's Travel and Wellness Blog Disclaimer: The contents of this podcast are intended for informational and educational purposes only. Always seek the guidance of your physician for any recommendations specific to you or for any questions regarding your specific health, your sleep patterns changes to diet and exercise, or any medical conditions.  Always consult your physician before starting any supplements or new lifestyle programs. All information, views and statements shared on the Live Greatly podcast are purely the opinions of the authors, and are not medical advice or treatment recommendations.  They have not been evaluated by the food and drug administration.  Opinions of guests are their own and Kristel Bauer & this podcast does not endorse or accept responsibility for statements made by guests.  Neither Kristel Bauer nor this podcast takes responsibility for possible health consequences of a person or persons following the information in this educational content.  Always consult your physician for recommendations specific to you.

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) CEO Jeremy Skillington and Principal Scientist Liam Tremble talked with Proactive's Stephen Gunnion about the company's involvement in the RISE research programme focused on cytokine release syndrome (CRS) in cancer immunotherapy. The University of Manchester and The Christie NHS Foundation Trust research programme titled RISE —short for Reducing Immune Stress from Excessive cytokine release from advanced therapies—is led by Dr Jonathan Lim and has received a £3.4 million grant from the UK's Medical Research Council. Skillington explained that Poolbeg Pharma will act as the lead business partner alongside Johnson & Johnson, and other partners. Poolbeg's previously announced upcoming TOPICAL trial examining its lead candidate POLB 001 will play a central role in the programme. Importantly, Johnson & Johnson will provide the approved bispecific antibody, teclistamab, for that trial. “We're very proud that POLB 001 has actually played a really key part to this,” Skillington said. Tremble noted the growing clinical challenge posed by CRS in advanced immunotherapies and how POLB 001 may offer a solution. “This really puts POLB 001 in a centrepoint position in cytokine release syndrome as a potential solution,” he said. The company confirmed the initiative will not impact its cash runway into 2027, nor will it impact delivery of the TOPICAL trial, with interim data expected in summer 2026. Visit Proactive's YouTube channel for more interviews and updates. Don't forget to like this video, subscribe, and turn on notifications to stay informed. #PoolbegPharma #POLB001 #CancerImmunotherapy #CRS #CytokineReleaseSyndrome #UKLifeSciences #BiotechNews #MedicalResearch #MRCGrant #ClinicalTrials #ImmunotherapySafety

This episode covers: Cardiology This Week: A concise summary of recent studies DAPT: how short is too short Obesity and atrial fibrillation Milestones: COURAGE  Host: Emer Joyce Guests: Carlos Aguiar, Steffen Massberg, Prash Sanders Want to watch that episode? Go to: https://esc365.escardio.org/event/2178 Want to watch that extended interview on dual antiplatelet therapy (DAPT) and shortening its optimal duration, go to: https://esc365.escardio.org/event/2178?resource=interview   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Emer Joyce, Nicolle Kraenkel and Steffen Massberg have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Prashanthan Sanders has declared to have potential conflicts of interest to report: advisory board representative University of Adelaide, Medtronic, Boston Scientific, CathRx, Abbott and Pacemate as well as research grants for University of Adelaide: Medtronic, Abbott, Boston Scientific, Becton Dickson. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Live from InfoSec World 2025, this episode of Enterprise Security Weekly features six in-depth conversations with leading voices in cybersecurity, exploring the tools, strategies, and leadership approaches driving the future of enterprise defense. From configuration management and AI-generated threats to emerging frameworks and national standards, this special edition captures the most influential conversations from this year's conference. In this episode: -You Don't Need a Hacker When You Have Misconfigurations — Rob Allen, Chief Product Officer at ThreatLocker®, discusses how overlooked settings and weak controls continue to be one of the most common causes of breaches. He explains how Defense Against Configurations (DAC) helps organizations identify, map, and remediate configuration risks before attackers can exploit them. -Security Challenges for Mid-Sized Companies — Perry Schumacher, Chief Strategy Officer & Partner at Ridge IT Cyber, explores the evolving security challenges facing mid-sized organizations. He discusses how AI is becoming a competitive advantage, how mobility and third-party reliance complicate defenses, and what steps these organizations can take to improve resilience and efficiency. -The Rise of Security Control Management: Secure by Design, Not by Chance — Marene Allison, former CISO of Johnson & Johnson, introduces Security Control Management (SCM), a new software category that unifies control selection, mapping, validation, and enforcement. She explains how SCM transforms fragmented compliance programs into proactive, embedded defense. -Engineered for Protection: The Rise of Security Control Management — Ryan Heritage, Advisor at Sicura, continues the discussion on SCM, explaining how organizations can operationalize this approach to move from reactive reporting to proactive, data-driven defense. He highlights how automation and integration enable security decisions to be made at “the speed of relevance.” -The AI Threat: Protecting Your Email from AI-Generated Attacks — Patricia Titus, Field CISO at Abnormal Security, explores how cybercriminals are weaponizing generative AI to create sophisticated phishing and social engineering attacks. She shares practical strategies for defending against AI-generated threats and emphasizes why AI-based protections are now essential for modern enterprises. -Igniting Change: A Conversation with Dr. Ron Ross — Dr. Ron Ross, CEO at RONROSSECURE, LLC, shares insights from decades of pioneering work in cybersecurity, including the Risk Management Framework and Systems Security Engineering Guidelines. He discusses how leaders can apply these principles to strengthen resilience, foster innovation, and drive meaningful change across the cybersecurity landscape.   Segment Resources ThreatLocker® Defense Against Configurations (DAC): https://www.threatlocker.com/platform/defense-against-configurations Book a demo to see DAC in action. Visit https://securityweekly.com/threatlockerisw to learn more! This segment is sponsored by Ridge IT Cyber. Visit https://securityweekly.com/ridgeisw to learn more about them! Visit https://www.securityweekly.com/esw for all the latest episodes! Show Notes: https://securityweekly.com/esw-435

Live from InfoSec World 2025, this episode of Enterprise Security Weekly features six in-depth conversations with leading voices in cybersecurity, exploring the tools, strategies, and leadership approaches driving the future of enterprise defense. From configuration management and AI-generated threats to emerging frameworks and national standards, this special edition captures the most influential conversations from this year's conference. In this episode: -You Don't Need a Hacker When You Have Misconfigurations — Rob Allen, Chief Product Officer at ThreatLocker®, discusses how overlooked settings and weak controls continue to be one of the most common causes of breaches. He explains how Defense Against Configurations (DAC) helps organizations identify, map, and remediate configuration risks before attackers can exploit them. -Security Challenges for Mid-Sized Companies — Perry Schumacher, Chief Strategy Officer & Partner at Ridge IT Cyber, explores the evolving security challenges facing mid-sized organizations. He discusses how AI is becoming a competitive advantage, how mobility and third-party reliance complicate defenses, and what steps these organizations can take to improve resilience and efficiency. -The Rise of Security Control Management: Secure by Design, Not by Chance — Marene Allison, former CISO of Johnson & Johnson, introduces Security Control Management (SCM), a new software category that unifies control selection, mapping, validation, and enforcement. She explains how SCM transforms fragmented compliance programs into proactive, embedded defense. -Engineered for Protection: The Rise of Security Control Management — Ryan Heritage, Advisor at Sicura, continues the discussion on SCM, explaining how organizations can operationalize this approach to move from reactive reporting to proactive, data-driven defense. He highlights how automation and integration enable security decisions to be made at "the speed of relevance." -The AI Threat: Protecting Your Email from AI-Generated Attacks — Patricia Titus, Field CISO at Abnormal Security, explores how cybercriminals are weaponizing generative AI to create sophisticated phishing and social engineering attacks. She shares practical strategies for defending against AI-generated threats and emphasizes why AI-based protections are now essential for modern enterprises. -Igniting Change: A Conversation with Dr. Ron Ross — Dr. Ron Ross, CEO at RONROSSECURE, LLC, shares insights from decades of pioneering work in cybersecurity, including the Risk Management Framework and Systems Security Engineering Guidelines. He discusses how leaders can apply these principles to strengthen resilience, foster innovation, and drive meaningful change across the cybersecurity landscape. Segment Resources ThreatLocker® Defense Against Configurations (DAC): https://www.threatlocker.com/platform/defense-against-configurations Book a demo to see DAC in action. Visit https://securityweekly.com/threatlockerisw to learn more! This segment is sponsored by Ridge IT Cyber. Visit https://securityweekly.com/ridgeisw to learn more about them! Visit https://www.securityweekly.com/esw for all the latest episodes! Show Notes: https://securityweekly.com/esw-435

Live from InfoSec World 2025, this episode of Enterprise Security Weekly features six in-depth conversations with leading voices in cybersecurity, exploring the tools, strategies, and leadership approaches driving the future of enterprise defense. From configuration management and AI-generated threats to emerging frameworks and national standards, this special edition captures the most influential conversations from this year's conference. In this episode: -You Don't Need a Hacker When You Have Misconfigurations — Rob Allen, Chief Product Officer at ThreatLocker®, discusses how overlooked settings and weak controls continue to be one of the most common causes of breaches. He explains how Defense Against Configurations (DAC) helps organizations identify, map, and remediate configuration risks before attackers can exploit them. -Security Challenges for Mid-Sized Companies — Perry Schumacher, Chief Strategy Officer & Partner at Ridge IT Cyber, explores the evolving security challenges facing mid-sized organizations. He discusses how AI is becoming a competitive advantage, how mobility and third-party reliance complicate defenses, and what steps these organizations can take to improve resilience and efficiency. -The Rise of Security Control Management: Secure by Design, Not by Chance — Marene Allison, former CISO of Johnson & Johnson, introduces Security Control Management (SCM), a new software category that unifies control selection, mapping, validation, and enforcement. She explains how SCM transforms fragmented compliance programs into proactive, embedded defense. -Engineered for Protection: The Rise of Security Control Management — Ryan Heritage, Advisor at Sicura, continues the discussion on SCM, explaining how organizations can operationalize this approach to move from reactive reporting to proactive, data-driven defense. He highlights how automation and integration enable security decisions to be made at "the speed of relevance." -The AI Threat: Protecting Your Email from AI-Generated Attacks — Patricia Titus, Field CISO at Abnormal Security, explores how cybercriminals are weaponizing generative AI to create sophisticated phishing and social engineering attacks. She shares practical strategies for defending against AI-generated threats and emphasizes why AI-based protections are now essential for modern enterprises. -Igniting Change: A Conversation with Dr. Ron Ross — Dr. Ron Ross, CEO at RONROSSECURE, LLC, shares insights from decades of pioneering work in cybersecurity, including the Risk Management Framework and Systems Security Engineering Guidelines. He discusses how leaders can apply these principles to strengthen resilience, foster innovation, and drive meaningful change across the cybersecurity landscape.   Segment Resources ThreatLocker® Defense Against Configurations (DAC): https://www.threatlocker.com/platform/defense-against-configurations Book a demo to see DAC in action. Visit https://securityweekly.com/threatlockerisw to learn more! This segment is sponsored by Ridge IT Cyber. Visit https://securityweekly.com/ridgeisw to learn more about them! Show Notes: https://securityweekly.com/esw-435

Live from InfoSec World 2025, this episode of Enterprise Security Weekly features six in-depth conversations with leading voices in cybersecurity, exploring the tools, strategies, and leadership approaches driving the future of enterprise defense. From configuration management and AI-generated threats to emerging frameworks and national standards, this special edition captures the most influential conversations from this year's conference. In this episode: -You Don't Need a Hacker When You Have Misconfigurations — Rob Allen, Chief Product Officer at ThreatLocker®, discusses how overlooked settings and weak controls continue to be one of the most common causes of breaches. He explains how Defense Against Configurations (DAC) helps organizations identify, map, and remediate configuration risks before attackers can exploit them. -Security Challenges for Mid-Sized Companies — Perry Schumacher, Chief Strategy Officer & Partner at Ridge IT Cyber, explores the evolving security challenges facing mid-sized organizations. He discusses how AI is becoming a competitive advantage, how mobility and third-party reliance complicate defenses, and what steps these organizations can take to improve resilience and efficiency. -The Rise of Security Control Management: Secure by Design, Not by Chance — Marene Allison, former CISO of Johnson & Johnson, introduces Security Control Management (SCM), a new software category that unifies control selection, mapping, validation, and enforcement. She explains how SCM transforms fragmented compliance programs into proactive, embedded defense. -Engineered for Protection: The Rise of Security Control Management — Ryan Heritage, Advisor at Sicura, continues the discussion on SCM, explaining how organizations can operationalize this approach to move from reactive reporting to proactive, data-driven defense. He highlights how automation and integration enable security decisions to be made at "the speed of relevance." -The AI Threat: Protecting Your Email from AI-Generated Attacks — Patricia Titus, Field CISO at Abnormal Security, explores how cybercriminals are weaponizing generative AI to create sophisticated phishing and social engineering attacks. She shares practical strategies for defending against AI-generated threats and emphasizes why AI-based protections are now essential for modern enterprises. -Igniting Change: A Conversation with Dr. Ron Ross — Dr. Ron Ross, CEO at RONROSSECURE, LLC, shares insights from decades of pioneering work in cybersecurity, including the Risk Management Framework and Systems Security Engineering Guidelines. He discusses how leaders can apply these principles to strengthen resilience, foster innovation, and drive meaningful change across the cybersecurity landscape.   Segment Resources ThreatLocker® Defense Against Configurations (DAC): https://www.threatlocker.com/platform/defense-against-configurations Book a demo to see DAC in action. Visit https://securityweekly.com/threatlockerisw to learn more! This segment is sponsored by Ridge IT Cyber. Visit https://securityweekly.com/ridgeisw to learn more about them! Show Notes: https://securityweekly.com/esw-435

En la edición de hoy del Radar Empresarial, la atención se centra en una sola protagonista: Johnson & Johnson. La compañía ha alcanzado una capitalización bursátil cercana a los 500.000 millones de dólares, culminando uno de los periodos más favorables de su historia reciente. Sus acciones acumulan una subida del 42% en lo que va de año, y noviembre no ha hecho más que reforzar esta tendencia positiva. La empresa encadena 13 sesiones consecutivas al alza, la racha más prolongada de su trayectoria, y solo en este mes sus títulos avanzan un 9,9%, un ritmo que no se veía desde 2020. Detrás de este impulso se encuentra, en gran medida, su intensa estrategia de adquisiciones. A comienzos de año, Johnson & Johnson cerró un acuerdo para comprar Intra-Cellular Therapies, fabricante especializado en tratamientos neurológicos, en una operación valorada en más de 14.000 millones de dólares, la cuarta compra más relevante en su historia. Con este movimiento, la empresa buscaba reforzar su división de fármacos y dispositivos médicos tras la separación, en 2023, de su negocio de Consumer Health. Esta escisión dio origen a la empresa independiente Kenvue, que también ha sido noticia recientemente después de que Kimberly-Clark haya pactado su adquisición por casi 50.000 millones de dólares. Esta desinversión permite a Johnson & Johnson no solo obtener una cantidad significativa de recursos, sino también consolidar la estrategia que tan buenos resultados le está proporcionando: concentrarse en la farmacéutica avanzada y las tecnologías médicas. En esa misma línea, este mes anunció la compra de Halda Therapeutics, un laboratorio centrado en terapias contra tumores sólidos, lo que refuerza su catálogo oncológico y abre nuevas oportunidades de crecimiento para los próximos años. Las previsiones internas de la compañía sugieren que el impulso continuará. Johnson & Johnson estima un aumento operativo de las ventas de entre el 4,8% y el 5,3% en 2025, y anticipa que en 2026 los ingresos crecerán por encima del 5%. Además, destaca por su rápida alineación con la nueva administración estadounidense, al anunciar un plan de inversiones de 50.000 millones de dólares en Estados Unidos para los próximos cuatro años.

Sarah Kinlin returns to This Commerce Life two and a half years after her first appearance, and the transformation is remarkable. What started as a tentative step toward professional speaking has evolved into a thriving business as a mindset and leadership coach, author, and professional hockey coach.In this heartfelt conversation, Sarah shares her journey from leaving Johnson & Johnson to building a multi-faceted career centered on helping others go from tired and overwhelmed to rested and focused. She discusses writing her book "Grit, Grace & Goals" – a tribute to her late fathhttps://sarahkinlin.com/pages/grit-grace-mindset-coachinger's leadership lessons from raising nine kids while working at a nuclear station – and how her own childhood shaped her approach to coaching young athletes and business leaders alike.Sarah opens up about the grief recovery work that led to her book, the unexpected success of her book tour, coaching U15 girls' hockey, and the challenges of entrepreneurship. From meditation practices to managing hockey teams to running leadership workshops, this episode captures the reality of building a purpose-driven business while staying true to your values.Whether you're considering a career transition, navigating the loneliness of entrepreneurship, or looking for inspiration on how to turn life lessons into impact, Sarah's story offers practical wisdom wrapped in authenticity. This is Sarah's original podcast episode (episode 314) https://this-commerce-life-fb5a846c.simplecast.com/episodes/we-meet-a-fan-become-fans-sarah-kinlin-will-be-a-world-reknowned-speaker-coach-and-educator-were-proud-to-be-her-first-podcast Check out Sarah's website here: https://sarahkinlin.com/pages/grit-grace-mindset-coaching Thank you to Field Agent Canada for supporting the podcast: https://www.fieldagentcanada.com/  

In this episode of JCO Article Insights, host Dr. Ece Cali Daylan interviews author Dr. Jeffrey Bradley about the article, "Simultaneous Durvalumab and Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer" by Bradley, et al published October 13, 2025. TRANSCRIPT Dr. Ece Cali: Welcome to this episode of JCO Article Insights. This is Dr. Ece Cali, JCO Editorial Fellow. Today I'm joined by Dr. Jeffrey Bradley, Professor of Radiation Oncology at the University of Pennsylvania, to discuss the manuscript, "Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer: The Phase III PACIFIC-2 Study." The PACIFIC-2 study was a phase III, double-blind, randomized trial comparing the efficacy and safety of simultaneous durvalumab with concurrent chemoradiation followed by consolidation durvalumab to the concurrent chemoradiation followed by placebo in patients with unresectable stage III non-small cell lung cancer. The primary endpoint was progression-free survival by blinded independent central review. The secondary endpoints were overall response rate, overall survival, and safety. Three hundred twenty-eight patients were randomized 2:1 to durvalumab and placebo, respectively. Unfortunately, this trial did not meet its primary endpoint. There were no statistically significant differences in PFS or OS. The frequency of adverse events was similar between the two arms. Grade 3 or higher adverse events were observed in 53% of the patients in the durvalumab arm compared to 59% of the patients in the placebo arm. Of note, the frequency of pneumonitis was similar in the two arms. Approximately 28% of patients in each arm developed pneumonitis, and about 5% of the pneumonitis observed in each arm was grade 3 or higher in severity. Treatment discontinuation rates secondary to the adverse events were higher in the durvalumab arm, 25% compared to 12%. Adverse events leading to treatment discontinuation and death were more frequently seen in the durvalumab arm during the first four months of the treatment, which corresponds to the simultaneous administration of chemoradiation and durvalumab. Dr. Bradley, before we delve into the results, can you please explain the rationale for this study design and how this concept fits into the current treatment landscape? Dr. Jeffrey Bradley: Yeah, this trial came on the heels of PACIFIC after there was a progression-free survival benefit showed in PACIFIC that in the locally advanced unresectable population that consolidation immunotherapy, in this case durvalumab, had a progression-free survival benefit. A number of us in the clinical trial space thought to add concurrent immunotherapy in addition to consolidation immunotherapy that that would also improve outcomes for patients. So a number of trials were launched to follow up of PACIFIC. In this case, this is a phase III trial where the control arm was placebo. There was no overall survival results yet from PACIFIC, just a PFS benefit, and a number of countries across the world had not approved maintenance durvalumab in this space. So this trial looked at the experimental arm, which was concurrent immunotherapy, durvalumab, and chemoradiation followed by consolidation durvalumab versus placebo. Dr. Ece Cali: And if we were to focus on the safety profile first, an increased pneumonitis risk was a theoretical concern when immunotherapy is given concurrently with radiation. Do we see any major differences in the safety profile between the two arms in this trial? Dr. Jeffrey Bradley: No, and we were concerned about the addition of concurrent immunotherapy and chemoradiation, like you said, towards concern about increased pneumonitis rate, but we did not see increased pneumonitis in the experimental arm over placebo. And the grade 3 or higher, as you said, it was roughly 5%, more or less, in both arms, so we didn't see increase in pneumonitis toxicity with concurrent IO and chemoradiation. Dr. Ece Cali: But interestingly though, despite the lack of significantly increased toxicity with durvalumab, unfortunately, administering immunotherapy simultaneously with chemoradiation therapy did not improve survival. Lack of superiority of this treatment regimen, as you mentioned, is further confirmed across multiple similar negative trial readouts such as ECOG-ACRIN 5181 and CheckMate 73L. Dr. Bradley, in your view, what are some potential explanations for why this strategy did not pan out in clinical trials? Dr. Jeffrey Bradley: Regarding toxicity, let me go back and point out that we did see an increased number of immune-mediated adverse events. It was 34.7% in the concurrent immunotherapy arm versus 15.7% in the placebo arm. So that led to a higher number of discontinuations of immunotherapy which I think probably had an effect. So we didn't... there was an increased pneumonitis toxicity, but there were expected immune-mediated toxicities that caused people to stop giving immunotherapy. You can see that in the PFS curves. They were, you know, they crossed over after like a month, but initially there was lower PFS for the experimental arm, and then the experimental arm got better after we divided into four months, before four months and after four months. Dr. Ece Cali: For one reason or another, it looks like the simultaneous administration did not really improve outcomes. We now know that simultaneously giving them another concurrent radiation should really no longer be pursued in clinical trials for this patient population. Can you share with our audience what strategies are being studied in this setting and what trials to watch out for in the future? Dr. Jeffrey Bradley: Sure, I think when you add concurrent radiation to immunotherapy, there were more central tumors in this trial, I think you're killing lymphocytes and negating the effect of immunotherapy. So I think that's the smoking gun for this trial, for the ECOG trial, for the small cell trial that NRG reported, LU005, and other trials. So correct, I don't think there's any need to continue to pursue concurrent immunotherapy in this space of lung cancer. But that's not to say there aren't many other trials that are either ongoing, have accrued and awaiting results, or being planned for the next phase of clinical trials. We have a trial within NRG Oncology called NRG-LU008. It's a randomized phase III trial that is using an SBRT boost to a peripheral primary and chemoradiation to the nodes, because the primary tumor is the one that fails more often than the lymph nodes, and that's compared to PACIFIC in the control arm. PACIFIC-9 is another trial in the same line as the other PACIFIC trials. That one is using dual checkpoint inhibition versus the control arm being PACIFIC. So there are three arms in that trial, durva and oleclumab, durva and monalizumab versus the PACIFIC arm. And that trial is completed accrual, but we have no results from that study yet. Johnson & Johnson has a trial open looking at a nanoparticle. That's a radiosensitizer where bronchoscopy is used to inject the primary tumor and the lymph nodes with a radiosensitizer. That's a randomized phase ll trial that's ongoing. It's got three arms, two different doses of this radiosensitizing drug and then a control arm without injection at all. The control arm is again the PACIFIC arm. And then those of us within the NCI-based clinical trials evaluation program, CTEP, are proposing an intergroup trial that would compare induction chemo-immunotherapy followed by chemoradiation followed by maintenance immunotherapy versus PACIFIC in a phase III study. So I think there's other trials that are either completed, ongoing completed, or on the horizon to assess in this patient population. Dr. Ece Cali: Yeah, we definitely have an unmet need to improve survival outcomes for stage III patients, and it's great to hear that there are so many efforts looking at different strategies to improve outcomes for these patients.  Thank you so much, Dr. Bradley, for this informative discussion and for sharing your insights. Any last thoughts? Dr. Jeffrey Bradley: Yeah, we need something, you know. PACIFIC was first reported in 2017, and we really haven't made progress in terms of changing that standard of care control for the last eight years. So we need progress in this area. Dr. Ece Cali: Yep, definitely. Thank you so much for joining, Dr. Bradley.  And thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. DISCLOSURES Dr. Bradley Honoria: Mevion Medical Systems, Inc. Consulting or Advisory Role: Varian, Inc, Genentech, Inc. Research Funding: Varian Medical Systems Dr. Cali Research Funding Company: BeiGene, Nuvalent, Inc., Astra Zeneca 

In this special 20th-anniversary episode of Bladder Cancer Matters, host and survivor Rick Bangs sits down with leading urologic oncologist Dr. Sia Daneshmand to explore a new bladder cancer therapy: Johnson & Johnson's newly FDA-approved INLEXZO™. Dr. Daneshmand—who helped lead its clinical trials—breaks down how this "pretzel-shaped" intravesical delivery system works, why it's showing some of the highest response rates yet for BCG-unresponsive disease and what patients can realistically expect in terms of side effects, treatment schedule, and quality of life. Together, they discuss the future of drug-delivery technology in bladder cancer and why this moment can offer hope to bladder cancer patients.

This episode covers: Cardiology This Week: A concise summary of recent studies 'ChatGPT, MD?' - Large Language Models at the Bedside Management decisions in myocarditis Statistics Made Easy: Mendelian randomisation Host: Emer Joyce Guests: Carlos Aguiar, Folkert Asselbergs, Massimo Imazio Want to watch that episode? Go to: https://esc365.escardio.org/event/2179 Want to watch that extended interview on 'ChatGPT, MD?': Large Language Models at the Bedside? Go to: https://esc365.escardio.org/event/2179?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Folkert Asselbergs, Yasmina Bououdina, Massimo Imazio, Emer Joyce, and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Folkert Asselbergs Want to watch that episode? Go to: https://esc365.escardio.org/event/2179 Want to watch that extended interview on 'ChatGPT, MD?': Large Language Models at the Bedside? Go to: https://esc365.escardio.org/event/2179?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.  Declarations of interests: Stephan Achenbach, Folkert Asselbergs, Yasmina Bououdina, Emer Joyce, and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. E mma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This week, we interviewed Ken Sher, who is an Executive Coach, Career Coach, Keynote Speaker, and, most recently, an author. Ken spent more than 25 years at Johnson & Johnson in leadership roles across Sales, Marketing, Recruiting, Training, and Leadership Development. Through his experience, Ken has seen that technical skills alone don't make leaders successful. The best leaders are compassionate, authentic, and know how to build strong, trusting relationships that help teams thrive. He brings these lessons to life in his book, What's TRUST Got to Do with It? Transforming Leadership, Culture, and the Job Search, where he shows how trust becomes the foundation for meaningful relationships and how those relationships drive results.  

In a world that often dismisses the extraordinary as mere fantasy, the Webby Award winning podcast, The Telepathy Tapes, dares to listen instead.What began as a documentary investigation into the remarkable telepathic abilities of non-speaking individuals with autism has expanded into a global exploration of consciousness itself – the science behind it, the mysteries within it, and the lived experiences that refuse to be ignored.In Season One, non-speaking autistic individuals revealed striking abilities that challenge everything we thought we knew about the mind. In Season Two, the lens widens to extraordinary phenomena that invite us to rethink reality itself. From near death experiences to telepathic communication with animals, energy healing to plant intelligence, and the origins of creativity to sudden savant abilities -- each episode offers a rare glimpse into the vast terrain of consciousness beyond the brain.Most people do not live at the extremes of blind belief or hard-nosed skepticism and nobody wants to be fooled in either direction. Award-winning filmmaker Ky Dickens is your host in this paradigm-shifting series that navigates the space between proof and possibility, where transparency, curiosity, and open-minded skepticism meet to help listeners uncover answers to the mysteries that science hasn't fully explained. What have we dismissed that may be true? Is consciousness something we access, or is it bound to the brain? Does it survive death? Can it connect across time and space? And what might it mean for all of us?Step inside a conversation that sits between science and mystery, skepticism and wonder. This is The Telepathy Tapes.BioKy Dickens is an award-winning filmmaker celebrated for her transformative documentaries that tackle complex social issues, influence public policy, and ignite cultural change. Known as a storyteller at the intersection of film and societal impact, she has received numerous accolades, including the Focus Award for Achievement in Directing and the Change Maker Award for advancing social change through art and film.Ky's fifth film, Show Her the Money, featuring Elizabeth Banks and Sharon Gless, was named one of the decade's best financial films by U.S. News & World Report. The film has won three Jury Prizes for Best Documentary, including from the Los Angeles International Film Festival.In 2024, Ky created The Telepathy Tapes, a podcast exploring telepathy within the nonspeaking community and raising profound questions about consciousness, language, and inclusion. The series went viral upon release, and in December 2024, it surpassed Joe Rogan as the number one podcast in the world. In 2025, The Telepathy Tapes won a Webby Award for Best Indie Podcast and was nominated for Podcast of the Year by iHeartRadio. The series is currently being developed into a documentary feature film set for release in 2026.Her film Zero Weeks (Amazon), about America's paid leave crisis, debuted its trailer at the White House Summit on the State of Women, hosted by Oprah and Michelle Obama. Ky's other notable projects include The City That Sold America (Freestyle Releasing), a deep dive into Chicago's pivotal role in American consumer culture, and Sole Survivor (CNN Films), a haunting profile of lone survivors of otherwise fatal plane crashes. Her film #TimeToCare, which premiered at SXSW and was screened for the United States Congress in 2021. The film explores caregiving through the lens of social influencers whose journeys captivated millions on TikTok.Between 2019 and 2021, Ky directed the award-winning short film series Critical Condition, On the Edge, and Left Behind, which highlighted Americans suffering due to the Medicaid Gap. Her first narrative film, In the Jungle, is set to be released in 2024. Collectively, Ky's films have garnered over 20 awards, including audience choice, best film, and best directing honors.In addition to her feature work, Ky directs commercials for major global brands, including Netflix, Google, TikTok, and Johnson & Johnson. She is an active member of Film Fatales Los Angeles and the Directors Guild of America.A lifelong advocate for the special needs community, Ky spearheaded her district's inclusion program when she was in high school. She graduated magna cum laude from Vanderbilt University and lives in Los Angeles, California, with her family, rescue dog, Devon Rex cats, and Kombucha scoby.https://thetelepathytapes.com/ https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlifeMy book 'Verified Near Death Experiences' https://www.amazon.com/dp/B0DXKRGDFP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This Day in Legal History: Pennsylvania Coal Co. v. MahonOn this day in legal history, November 14, 1922, the Supreme Court heard arguments in Pennsylvania Coal Co. v. Mahon, a foundational case in American property law. At issue was a Pennsylvania statute—the Kohler Act—that prohibited coal mining beneath certain structures to prevent surface subsidence. The Pennsylvania Coal Company had previously sold the surface rights to a parcel of land but retained the right to mine the coal beneath. When the state blocked their ability to do so, the company sued, arguing that the law had effectively stripped them of valuable property rights without compensation. The case reached the Supreme Court, where Justice Oliver Wendell Holmes Jr. delivered the majority opinion.In his decision, Holmes introduced the now-famous principle that “while property may be regulated to a certain extent, if regulation goes too far it will be recognized as a taking.” This line marked the birth of the regulatory takings doctrine, which holds that government actions short of full appropriation can still require just compensation under the Fifth Amendment. Holmes emphasized that the economic impact of a regulation on the property owner must be weighed, not just the public interest it serves. In this case, the regulation was deemed too burdensome to be considered a mere exercise of police power.The Court sided with the coal company, holding that the Kohler Act, as applied, amounted to an unconstitutional taking. The dissent, penned by Justice Brandeis, warned against undermining states' ability to protect public welfare. Despite being a 5–4 decision, Mahon has had lasting influence on land use, zoning, and environmental regulation. It reframed the boundaries between public regulation and private rights, signaling that not all public-interest laws are immune from constitutional scrutiny. Today, Mahon remains a cornerstone case for litigants challenging regulations that significantly diminish property value.A Texas judge is set to hear arguments on Attorney General Ken Paxton's request to block Kenvue from issuing a $398 million dividend and from marketing Tylenol as safe during pregnancy. Paxton sued Kenvue in October, accusing the company of hiding risks linked to prenatal Tylenol use, including autism and ADHD—a claim not supported by the broader medical community. The lawsuit follows public comments by Donald Trump and Robert F. Kennedy Jr. promoting the same unproven theory. Kenvue and Johnson & Johnson, which previously owned Tylenol, maintain the drug's safety and argue the state has no authority to interfere in federal drug regulation or corporate dividends.The companies also say the dividend will not impair Kenvue's solvency and warn that Paxton's effort could undermine both the First Amendment and the credibility of Texas courts. Paxton, however, argues that the public interest justifies intervention, citing potential future liabilities from Tylenol and talc-related lawsuits. He contends that misleading commercial speech can be regulated, and that the dividend should be halted to preserve cash in the face of those risks. The case could have broader implications, particularly for Kimberly-Clark's $40 billion acquisition of Kenvue, announced shortly after the lawsuit. Kenvue has vowed to appeal any injunction.Judge to weigh if Texas AG can block Kenvue dividend over Tylenol claims | ReutersSierra Leone has reached a tentative settlement with U.S. law firm Jenner & Block to resolve a dispute over $8.1 million in unpaid legal fees. The law firm sued the West African nation in 2022, claiming it was still owed money for representing Sierra Leone in a high-stakes case against Gerald International Ltd., which had sought $1.8 billion in damages over an iron ore export ban. Jenner argued the legal work was more extensive than initially expected and said it had only been paid $3.6 million by the end of 2021.Sierra Leone pushed back, disputing the existence of a valid contract and asserting that no further payments were owed. The country also tried to claim sovereign immunity, but a federal judge rejected those arguments in January, allowing the lawsuit to proceed. U.S. Magistrate Judge G. Michael Harvey announced the settlement in principle last week, although specific terms were not disclosed. Neither party has commented publicly on the resolution.Sierra Leone, law firm Jenner & Block reach settlement over $8 million legal tab | ReutersMcDermott Will & Emery has become the first major U.S. law firm to publicly confirm that it is considering private equity investment, signaling a potential shift in how Big Law might operate. The firm's chairman acknowledged preliminary talks with outside investors, a move that stunned the legal industry, where non-lawyer ownership has long been resisted due to ethical and regulatory restrictions. McDermott is reportedly exploring a structure that would separate its legal services from administrative operations by creating a managed service organization (MSO) owned by outside investors, allowing the firm to raise capital without violating professional conduct rules.This model has gained traction among smaller firms, but McDermott's adoption could legitimize the MSO approach for large firms. Proponents argue it would free lawyers to focus on client work while upgrading support systems through external funding. Critics caution that it involves relinquishing control of critical firm functions and raises concerns about maintaining ethical standards, particularly regarding fee-sharing with non-lawyers. While still early, industry experts say other firms are beginning to explore similar paths to stay competitive, especially in jurisdictions like Arizona that allow non-lawyer ownership.McDermott's Outside Investor Talks Augur Big Law TransformationThe Trump administration has filed suit against California over its recently approved congressional redistricting maps, which were adopted through a ballot initiative known as Proposition 50. The measure, passed by voters last week, allows temporary use of new district lines that could give Democrats up to five additional U.S. House seats. The Justice Department joined a lawsuit initially filed by the California Republican Party and several voters, alleging that the redistricting plan was racially motivated and unconstitutional.U.S. Attorney General Pam Bondi called the maps a “brazen power grab,” accusing California of using race to unlawfully boost Hispanic voting power. California Governor Gavin Newsom dismissed the lawsuit, framing it as retaliation for California's resistance to Trump's broader political agenda. Newsom also argued that the new maps are a necessary corrective to Republican-led gerrymandering efforts, like those in Texas, where civil rights groups have sued over alleged dilution of minority voting power.The lawsuit claims California's map violates the U.S. Constitution by improperly using race in the redistricting process. The outcome could impact the balance of power in the House and add fuel to ongoing legal battles over partisan and racial gerrymandering nationwide.Trump administration sues California over new redistricting maps | ReutersThis week's closing theme is by Ludwig van Beethoven, a composer of some note.This week's closing theme is the first movement of Ludwig van Beethoven's Symphony No. 8 in F Major, Op. 93 – I. Allegro vivace e con brio, a work that balances classical clarity with Beethoven's unmistakable wit and rhythmic drive. Composed in 1812 during a period of personal turmoil, the Eighth is often described as a cheerful outlier among his symphonies, compact and effervescent despite being written amid deteriorating health and emotional strain. It was premiered in 1814, but it was a revival performance on November 14, 1814, in Vienna that helped solidify its reputation and gave the public a second opportunity to appreciate its lightness and humor in contrast to the more dramatic works surrounding it.Unlike the grand scale of the Seventh or Ninth, the Eighth is shorter and more classical in form, often drawing comparisons to Haydn in its wit and economy. Yet Beethoven infuses it with his unique voice—syncopations, dynamic extremes, and abrupt harmonic shifts abound, particularly in the first movement. The Allegro vivace e con brio opens with a bold, playful theme, tossing melodic fragments between the orchestra with cheerful assertiveness. It's less stormy than many of Beethoven's first movements, but no less commanding.Critics at the time were puzzled by the symphony's restraint and humor, expecting more overt heroism from Beethoven. But modern listeners often recognize the Eighth as a masterwork of compression and invention. The first movement in particular plays with rhythmic momentum, frequently disrupting expectations just as they form. There's a confidence in its restraint, a knowing smile behind the forceful accents and offbeat rhythms. It's music that's both technically impressive and viscerally enjoyable, which is perhaps why Beethoven held it in especially high regard.As we close out the week, we leave you with that November 14 revival spirit—a reminder that even a “little Symphony” can land with enduring force.Without further ado, Ludwig van Beethoven's Symphony No. 8 in F Major, Op. 93 – I. Allegro vivace e con brio, enjoy! This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Dr Tasha Eurich is an organisational psychologist, researcher, and NY Times bestselling author. Her 2017 TEDx talk has garnered over 10 million views. Her work has appeared in The WSJ, NY Times, HBR, CNN, NBC, Fast Company, and various peer-reviewed journals. Trusted by some of the world's most influential leaders—including Fortune 500 CEOs and clients like Google, Walmart, Salesforce, Johnson & Johnson, and the White House Leadership Development Program—Tasha was named one of the world's most influential coaches by Thinkers50. In this conversation, we discuss her new book, 'Shatterproof: How to Thrive in a World of Constant Chaos (And Why Resilience Alone Isn't Enough).'   LINKS   Tasha's website tashaeurich.com   Book on Amazon Shatterproof: How to Thrive in a World of Constant Chaos (And Why Resilience Alone Isn't Enough)   The Mojo Sessions website www.themojosessions.com   The Mojo Sessions on Patreon www.patreon.com/TheMojoSessions Full transcripts of the show (plus time codes) are available on Patreon.   The Mojo Sessions on Facebook www.facebook.com/TheMojoSessions   Gary on LinkedIn www.linkedin.com/in/gary-bertwistle   Gary on Twitter www.twitter.com/GaryBertwistle   The Mojo Sessions on Instagram www.instagram.com/themojosessions   If you like what you hear, we'd be grateful for a review on Apple Podcasts or Spotify. Happy listening!   © 2025 Gary Bertwistle.  All Rights Reserved.  

Dr. Haley Perlus is a Doctor of Performance Psychology, speaker, author, and coach specializing in sport-specific techniques to optimize the mental game for athletes and high achievers. With a PhD in Sport Psychology, MS in Sport Pedagogy, and certifications in coaching, fitness, and nutrition, she draws from her elite athlete background to deliver practical strategies. Haley has worked with Marriott, Starbucks, NASA, Johnson & Johnson, Deloitte, U.S. Air Force, Oprah, and ESPN on embracing pressure, building focus, and overcoming mental blocks. Author of Personal Podium, her keynotes like "Harnessing Stress as a Performance Enhancer" and "Optimal Energy Flow for Success" help turn stress into power and sustain energy. Her philosophy—"Perform with heart. Win with mind"—guides Olympic hopefuls and executives toward peak performance and well-being.ParentShift course 30% off with the code TRIBE. Link below: ParentShift (English): https://www.hernanchousa.com/courses/parentshift?ref=c23daaEntrena Tu Legado (Spanish): https://www.hernanchousa.com/courses/entrenatulegado?ref=c23daaConnect with Haley on LinkedIn: Haley PerlusOther Social Media Links for Haley:Instagram: @drhaleyperlus Youtube: @drhaleyperlusWebsite: https://drhaleyperlus.com/Haley's book "Personal Podium: How to Use Your Mind to Maximize Your Potential in Sport and Life" You can explore more of Hernan's work on his website, https://www.hernanchousa.com/.Music Production by Sebastian Klauer. You can reach him at klauersebas@gmail.com. 

Episode 10 - Stephanie Karzon Abrams: Heart and Science This episode takes on a wide ranging ride inside Stephanie's wildy diverse experise on the science of psychedelics to the importance of music and community. Stephanie is a profound and powerful voice in the psychedelic community and her work represents the best of the modern psychedelic movement.  Intro: Ann Shulgin takes on a brief exploration of the shadow.  Stephanie Karzon Abrams is a neuropharmacologist, founder of Beyond Consulting—powering the integrative, psychedelic and plant medicine spaces, and is the co-founder of the Public Secret music label and artist collective.  She serves as Clinical Director at Modern Medicine Services, is a prescriber of MDMA and psilocybin therapy under Canada's SAP, and is the Research Director at the Microdosing Collective non profit.  Stephanie believes in the undercurrent of joy woven into the fabric of our existence and thus co-created the talk and event series "The Chemistry of Joy", where the human experience is explored through the lens of ritual and celebration.  With experience in neurology, intensive care, and medical device at Johnson & Johnson, she is a recognized leader in innovative healthcare. Her work bridges neuroscience, women's health, plant medicine, and the healing power of music. A musician, writer, and speaker, Stephanie also builds community through gatherings rooted in music, meaning, and mycology. Web: https://www.stephaniekarzonabrams.com  Www.Beyondconsulting.Life  Social: @steph__k @public.secret  @microdosingcollective @thechemistryofjoy @mod_meds

EPISODE 619 - Alex R. Johnson - Brooklyn Motto A coming-of-age,  New York-centric, detective noir debutALEX R. JOHNSONJohnson's feature film TWO STEP premiered to critical acclaim at SXSW and went on to become a New York Times Critic's Pick, as well as remaining 100% Fresh on Rotten Tomatoes. His screenplay NORTHEAST KINGDOM was selected for the Black List. It was acquired by Paramount Pictures for Platinum Dunes to produce, with Johnson attached to direct. His screenplay ANY ROUGH TIMES ARE NOW BEHIND YOU was selected by the Austin Film Society's Artist Intensive lab. There, he spent three days working one-on-one with late director Jonathan Demme, an experience that was as inspiring as it was creatively life changing. He also wrote the screenplay adaptation of Ernest Tidyman's novel, BIG BUCKS, for Pascal Pictures.His debut novel, BROOKLYN MOTTO, will be released in March of 2025.Prior to writing and directing, Johnson was a seasoned NYC based commercial and documentary producer. He started his career at the legendary Maysles Films and then branched off to work with other directors, including producing the feature documentary I AM SECRETLY AN IMPORTANT MAN for filmmaker Pete Sillen. Johnson's family hails from the Andes of Ecuador. A government brat, he moved frequently but was raised mostly between New York City and the suburbs of DC. He lives and works in Brooklyn, NY..BROOKLYN MOTTO by Alex R. JohnsonFans of Richard Price, Charlie Huston, and Jonathan Lethem will love this coming-of-age New York-centric detective noir debut from esteemed filmmaker and screenwriter Alex R. Johnson. New York City, 1998. New York is changing around Nico Kelly, and he can feel more coming. A private investigator and self-proclaimed photographer, Nico is stuck in a loop of city contracts and self loathing. What little middle class there was is disappearing—long-standing factories are moving out and taking their reliable neighborhood jobs with them, and Mayor Rudy Giuliani's police force has the streets in a stranglehold. Nico spends his days looking for fraudsters while taking photos of municipal employees on disability claims. He spends his nights trying to get rid of the nagging feeling that his day job makes him a professional snitch—traversing dive bars, playing pinball, and fighting through the haze of hungover mornings and blurry evenings.Pushing thirty years old and feeling split between his American and Latin heritage, between youth and adulthood, Nico finds himself at a precipice—who is he and what should he become? When Nico witnesses and records a murder during one of his insurance fraud investigations, bodies start to turn up all around him and he's forced into solving a mystery he didn't ask to solve. Humorous, gritty, and real, Nico's search for what it means to be human takes him through the deepest and darkest parts of New York City.https://www.brooklynmotto.com/Support the show___https://livingthenextchapter.com/podcast produced by: https://truemediasolutions.ca/Coffee Refills are always appreciated, refill Dave's cup here, and thanks!https://buymeacoffee.com/truemediaca

This episode covers: Cardiology this Week: A concise summary of recent studies Lp(a) - What to expect in the very near future Myocardial infarction in older and frail adults Mythbusters: is beetroot good for your heart? Host: Rick Grobbee Guests: JP Carpenter, Vijay Kunadian, Erik Stroes Want to watch that episode? Go to: https://esc365.escardio.org/event/2177 Want to watch that extended interview on Lp(a), go to: https://esc365.escardio.org/event/2177?resource=interview   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.    Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel, Vijay Kunadian and Erik Stroes have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this short podcast episode, Bryan explains how duct tape got its name and why it shouldn't actually be used on ducts. Duct tape is a versatile home DIY-fix tool, but despite its name, it wasn't initially made to seal ducts at all. In 1943, we were in the thick of World War II, and ammo shipments were sealed with wax and paper tape. These were often not durable or difficult to open. Johnson & Johnson developed a tape with rubber adhesive on a cotton duck cloth backing (which was already widely used for military uniforms and tent fabrics). This new tape was nicknamed "duck" tape due to the material and its waterproof abilities (like the waterfowl). A woman named Vesta Stoudt informed President FDR about duct tape, and the War Production Board began using it in wartime supply packaging. After the war, America had a housing boom in the 1950s, which included the demand for forced-air heating and cooling systems. Marketers thought the tape could seal the ducts in those homes, so they changed the color to match sheet metal and rebranded it as "duct tape." In the 1960s, this tape was available in retail outlets with the "duct tape" branding. Unfortunately, in tests by the Lawrence Berkeley National Lab, duct tape failed miserably at sealing the ducts because the rubber adhesive dries out under heat, and dust weakens the adhesive. As a result, many building codes ban duct tape on ducts (spearheaded by California). Instead, UL-listed foil tape and mastic are approved for sealing ducts. However, duct tape still became famous for its versatility as a patching material. It's prevalent in pop culture and has been used in television shows and even in space.   Have a question that you want us to answer on the podcast? Submit your questions at https://www.speakpipe.com/hvacschool. Purchase your tickets or learn more about the 7th Annual HVACR Training Symposium at https://hvacrschool.com/symposium. Subscribe to our podcast on your iPhone or Android. Subscribe to our YouTube channel. Check out our handy calculators here or on the HVAC School Mobile App for Apple and Android.

Texas Attorney General Ken Paxton has filed a lawsuit against Johnson & Johnson, alleging the company failed to warn that Tylenol taken during pregnancy could increase the risk of autism and ADHD. The move comes after President Trump's remarks on ignited public debate on the cause of autism and the safety of Tylenol.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This Day in Legal History: Black TuesdayOn October 29, 1929, the United States experienced one of the most catastrophic financial events in its history—Black Tuesday, the climax of the stock market crash that helped trigger the Great Depression. While primarily remembered as an economic crisis, this day also had profound and lasting legal consequences that reshaped American financial regulation and the federal government's role in the economy.In the immediate aftermath, the lack of oversight and rampant speculation that had fueled the 1920s bull market came under intense scrutiny. The legal system responded in the 1930s with a suite of landmark legislative reforms designed to stabilize financial markets and restore public confidence. Chief among these were the Securities Act of 1933 and the Securities Exchange Act of 1934, which established mandatory disclosure requirements for public companies and created the Securities and Exchange Commission (SEC) to enforce federal securities laws.These laws introduced the legal principle that corporations owe a duty of candor to investors and that misleading or fraudulent statements can be subject to civil and criminal penalties. They also laid the foundation for modern financial regulation, including rules governing insider trading, market manipulation, and fiduciary duties of brokers and advisors.The legal legacy of October 29, 1929, is thus not limited to market losses but includes the birth of a federal regulatory framework that continues to govern securities markets today. It marked a turning point where the federal government took a permanent role in policing Wall Street and protecting investors through statutory and administrative mechanisms.The U.S. Court of Appeals for the Second Circuit will hear Argentina's appeal of a $16.1 billion judgment related to its 2012 expropriation of oil company YPF. The judgment, issued by U.S. District Judge Loretta Preska in 2023, awarded $14.39 billion to Petersen Energia Inversora and $1.71 billion to Eton Park Capital Management, former minority shareholders of YPF. They claimed Argentina violated contractual obligations by failing to make a tender offer when it nationalized 51% of YPF from Spanish energy firm Repsol.Argentina argues the case should not be heard in a U.S. court, citing sovereign immunity, misapplication of Argentine law, and the principle of international comity. It also contends the damages are vastly overstated—amounting to 45% of its 2024 national budget. The litigation has been financially backed by Burford Capital, which could receive a large payout if the appeal fails.The appeal arrives as President Javier Milei, a libertarian reformer, works to stabilize Argentina's economy with austerity measures, having recently achieved a rare budget surplus. Meanwhile, Argentina is also separately appealing a court order to hand over YPF shares, an order currently on hold. The U.S. government has not taken a stance on the appeal but opposed the share turnover, citing foreign policy risks.Argentina to ask US appeals court to overturn $16.1 billion YPF judgment | ReutersA federal judge ruled that Bilal Essayli was unlawfully appointed as acting U.S. attorney for California's Central District, which includes Los Angeles. U.S. District Judge J. Michael Seabright found that Essayli's continued service beyond the 120-day interim period allowed by law was improper since he had neither been nominated by the president nor confirmed by the Senate. This decision disqualifies him from serving in the acting role but allows him to remain as first assistant U.S. attorney.The ruling does not dismiss three criminal indictments issued during Essayli's tenure, as they were signed by other prosecutors and no due process violations were found. Still, the judgment raises concerns about leadership stability in the largest federal judicial district in the country, serving roughly 19 million people.Essayli's appointment was part of a broader pattern under the Trump administration of bypassing Senate confirmation for key prosecutorial roles. A similar ruling recently invalidated the acting U.S. attorney appointment in Nevada, and another decision in New Jersey blocked Alina Habba, a Trump ally, from participating in prosecutions. These appointments are now under appeal.Judge disqualifies ‘acting' US attorney in California | ReutersThe celebrity video platform Cameo filed a trademark infringement lawsuit against OpenAI in a California federal court, accusing it of unlawfully using the name “Cameo” for a new feature in its Sora video generation app. Cameo claims that OpenAI's use of the term for AI-generated virtual likenesses causes brand confusion and threatens the distinctiveness of its trademark.OpenAI launched Sora as a standalone app in late September, and its feature—also named “Cameo”—lets users create AI-generated videos that can include virtual celebrities. Cameo argues this directly competes with its own service, where users pay real celebrities for personalized video messages. The company pointed to examples of AI-generated videos featuring public figures like Mark Cuban and Jake Paul, claiming this puts OpenAI in head-to-head competition with their business model.Cameo said it attempted to resolve the issue privately, but OpenAI declined to change the feature's name. OpenAI responded that it disagrees with the lawsuit, arguing no one can monopolize a generic term like “cameo.”The lawsuit seeks financial damages and a court injunction to stop OpenAI from using the name “Cameo.”OpenAI sued for trademark infringement over Sora's ‘Cameo' feature | ReutersTexas has hired the law firm Keller Postman—which previously secured a $1.4 billion settlement from Meta—to lead a new lawsuit alleging that Tylenol use during pregnancy increases the risk of autism in children. Filed in Panola County, the suit accuses Johnson & Johnson and Kenvue, Tylenol's current owner, of misleading consumers by marketing the drug to pregnant women despite knowing potential developmental risks tied to its active ingredient, acetaminophen.Ashley Keller, a senior partner at the firm, said the case will be handled on a contingency basis, meaning Texas pays only if it wins, similar to prior deals with Meta and Google. The firm's effective hourly rate under that model can reach $3,780, though its total fees are capped at 11% of any recovery. Keller defended the state's approach, saying the firm invests heavily and shares the litigation risk with Texas.The lawsuit builds on ongoing national litigation over acetaminophen and childhood developmental disorders, though courts have previously rejected similar claims. A 2024 federal ruling in New York dismissed related cases after expert testimony linking acetaminophen to ADHD was excluded. Texas' case, however, is distinct because it focuses on state-level claims of deceptive trade practices and fraudulent transfer, alleging J&J unlawfully moved Tylenol liabilities to Kenvue.Texas Returns to Keller Postman to Link Tylenol to Child Autism This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

This week on the Power of Owning Your Career Podcast, host Simone Morris welcomes Keith Willis—leadership expert, entrepreneur, and Founder of Core Management Training. Keith's journey is indicative of how careers thrive by intentional design, not by chance. Starting out as a U.S. Army Junior Officer, Keith made the leap to corporate America through the Cameron-Brooks Development & Preparation Program, a pivotal experience that shaped his passion for helping others own their career trajectories. Keith built an impressive resume with award-winning roles in sales and training at industry giants such as Johnson & Johnson, Pfizer, and Bristol Myers Squibb, where he was recognized for his results as both a sales representative and a manager. Inspired by his drive to close the gap between individual performance and transformative leadership, Keith founded Core Management Training, where he equips pharmaceutical and life sciences organizations to turn managers into leaders who drive performance and culture. Today, Keith is also building "Never Look for a Job Again"—an e-zine and course designed to empower professionals to create opportunities rather than wait for them. He believes that anyone can own their career by embracing self-awareness, setting meaningful goals, and building supportive networks. In this candid and practical conversation, Keith shares actionable advice on navigating uncertainty, addressing ageism, and staying true to your authentic self—even when the workplace challenges you to fit in. Listeners will take away Keith's holistic formula for career ownership, practical resources, and the confidence to make bold moves—no matter where they're starting from. Resources Mentioned in the Episode: Never Look for a Job Again (career development guide and upcoming course) PCS to Corporate America by Cameron Brooks Manager Tools & Career Tools podcasts The Long View by Brian Fetherstonhaugh Self-development tools: Audible, LinkedIn Learning, and yes—even ChatGPT! Connect & Learn More: Host Simone E. Morris: LinkedIn | Become a Guest on the Show | 52 Tips for Owning Your Career Keith Willis: Core Management Training | Never Look for a Job Again Follow & Subscribe: Join us on IG at @simonemorrisent for career inspiration Subscribe to our YouTube for inclusive conversations and actionable career strategies Whether you're an aspiring leader, a career changer, or someone looking to unlock your full potential, this episode will inspire you to get behind the wheel of your career and drive your future forward.

This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Stephanie Schwarting Want to watch the episode? Go to: https://esc365.escardio.org/event/2176 Want to watch the extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests:  Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This Day in Legal History: Abrams v. United States ArguedOn October 21, 1919, the U.S. Supreme Court heard arguments in Abrams v. United States, a seminal case in the development of First Amendment jurisprudence. The case arose during the post–World War I Red Scare, when the government aggressively prosecuted speech perceived as dangerous or subversive. The defendants were Russian immigrants who distributed leaflets in New York City denouncing U.S. military intervention in the Russian Revolution and calling for a general strike. They were charged and convicted under the Sedition Act of 1918 for allegedly inciting resistance to the war effort.The Supreme Court upheld their convictions in a 7–2 decision, finding that the speech posed a “clear and present danger” to national security. However, it was Justice Oliver Wendell Holmes' dissent, joined by Justice Louis Brandeis, that left the most lasting impression. Holmes argued that only speech intended to produce imminent lawless action should be punished, introducing the enduring metaphor of the “marketplace of ideas” as essential to democratic deliberation.Legally, the case illustrates the government's ability to impose post-speech punishment—penalties after speech has occurred—as opposed to prior restraint, which involves preventing speech before it happens. The distinction is vital in American law: prior restraints are almost always unconstitutional, while post-speech sanctions may be permitted under narrow circumstances. In Abrams, the Court leaned toward deference to governmental wartime authority, but Holmes' dissent marked the beginning of a shift toward greater speech protections.The decision laid the groundwork for the more speech-protective standards adopted in later cases such as Brandenburg v. Ohio (1969). The post-speech punishment principle debated in Abrams remains a cornerstone of First Amendment law, highlighting the tension between state interests and individual liberties in times of political conflict.When two alleged drug traffickers survived a U.S. military strike in the Caribbean, the Trump administration immediately repatriated them rather than detain them — a decision that reveals a troubling logic behind the president's new “war” on narco‑terrorism. The administration has declared the campaign a “non‑international armed conflict,” but legal experts note that this classification offers no real authority for military detention. In other words, the United States can kill suspects under this self‑declared war framework, but it has no clear legal footing to hold survivors.Experts said the administration likely chose the least damaging option: send the survivors home and avoid a courtroom. Detaining them at Guantanamo or on U.S. soil would have triggered habeas corpus challenges, forced disclosure of evidence, and risked exposing the strikes as legally indefensible. One former State Department lawyer said any trial would have “undermined the narrative” that the attacks were lawful military operations. By refusing to hold prisoners, the administration sidesteps both judicial scrutiny and transparency.The result is a perverse incentive structure. If survivors are released but detainees are liabilities, the easiest path for officials is to ensure there are no survivors at all. The legal asymmetry—where killing is simpler than capture—encourages tactics that maximize lethality while minimizing accountability. As a result, Trump's “drug war” risks becoming less about law enforcement and more about ensuring that no one lives long enough to challenge the legality of U.S. actions.In Trump's drug war, prisoners may be too much of a legal headache, experts say | ReutersGlobal pharmaceutical companies are rapidly ramping up U.S. manufacturing in response to a looming Trump administration policy that would impose 100% tariffs on imported branded and patented drugs. While enforcement is delayed for companies that commit to domestic investment, the threat has already triggered a wave of fast-tracked spending, direct-to-consumer sales shifts, and pricing concessions in exchange for temporary tariff exemptions.Major players like Pfizer, AstraZeneca, Merck, Johnson & Johnson, Eli Lilly, and Roche have pledged tens of billions of dollars to build or expand plants across the U.S. to shield themselves from future penalties. Some, like Pfizer and AstraZeneca, secured multi-year tariff exemptions by agreeing to pricing deals and participation in the administration's new TrumpRx.gov program. Others, like Novartis and Sanofi, are spreading investments across multiple states and sites, creating thousands of jobs as part of their strategic insulation.The tariff threat is driving a major reshaping of global supply chains and investment strategies, as companies aim to avoid the legal and financial burden of import duties by domesticating both manufacturing and distribution. While some firms say they are already well-positioned with sufficient U.S. inventory, the broader trend reflects a defensive industry-wide shift to preemptively comply with the administration's protectionist push.Global drugmakers rush to boost US presence as tariff threat looms | ReutersTrevor Milton, the disgraced founder of electric-truck startup Nikola, is somehow back as a CEO—this time leading SyberJet Aircraft, a private jet manufacturer, according to reporting by Techdirt. Milton was convicted of fraud for deceiving investors about Nikola's technology, most famously releasing a misleading video of a prototype truck that was actually rolling downhill, not self-propelled. He was sentenced to four years in prison but never served a day, thanks to a pardon from Donald Trump earlier this year—reportedly after donating millions to Trump-aligned causes and hiring the brother of current Attorney General Pam Bondi as his attorney.Now, just months after that pardon, Milton has been tapped to lead development of a new high-speed jet for SyberJet, with promised performance metrics that already sound suspiciously ambitious. The company, privately backed, won't need to answer to public shareholders—but it will still need investor trust to raise money for a jet not slated for delivery until 2032. TechDirt points out how the company's promotional material leans into rewriting Milton's history, calling him “renowned” rather than acknowledging the full scope of his fraudulent past.The piece underscores a broader theme of “failing upward,” highlighting how white-collar offenders, especially white men with political connections, often land on their feet despite serious criminal convictions–and has some interesting implications for the future career of George Santos. Milton's quick rebound from federal fraud conviction to C-suite leadership is less an exception than a reminder of how accountability gaps persist in American corporate culture.Convicted Fraudster Trevor Milton Rides His Trump Pardon To Another CEO Job, Somehow | TechdirtIn my column for Bloomberg this week, I dive in to the governor's race in my home state. The 2025 New Jersey gubernatorial race has become a tax-policy showdown between Jack Ciattarelli and Mikie Sherrill—both of whom are framing affordability as their central mission, but doing so with deeply flawed approaches. Ciattarelli is offering aggressive tax cuts and structural overhauls that are, frankly, reckless in a state with a delicate and complicated fiscal ecosystem. His plan to flatten income tax brackets and slash corporate rates isn't just optimistic—it's ahistorical. We've seen this movie before in Kansas, where sweeping tax cuts led to revenue collapse, credit downgrades, and bipartisan regret. Ciattarelli is essentially proposing a rerun, but with no clearer escape plan if it fails.Sherrill, by contrast, is pragmatic to the point of inertia. Her emphasis on municipal service sharing and administrative tweaks is fine as far as it goes—but it doesn't go very far. Her promise to freeze utility rates via emergency powers, for instance, isn't just legally questionable, it also misdiagnoses the issue: state governments don't control wholesale energy prices. It's a symbolic gesture dressed up as policy.Neither candidate seems willing to address the structural drivers of New Jersey's notoriously high property taxes, preferring instead to nibble around the edges or promise caps that could backfire. That's a missed opportunity. As I argue in the column, New Jersey doesn't need sweeping cuts or more bureaucratic tinkering—it needs targeted relief for the people who actually feel the pinch. Expanding the state Earned Income Tax Credit and implementing a robust child tax credit would offer immediate, evidence-backed help to those struggling most with affordability. These aren't radical ideas; they're already working in other states.Ciattarelli's plan is built on trickle-down economics and wishful math. Sherrill's is built on competent management, but lacks ambition. The voters deserve more than either of those options.Tax Platforms in NJ Governor's Race Leave Out the Best Ideas This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

¡Emprendeduros! En este episodio Rodrigo nos da una actualización de mercado donde habla del estatus del mercado, de la reanudacion de la guerra comercial entre China y EEUU, del discurso de Jerome Powell y de una posible crisis en el credito privado. Nos da los reportes de ingresos de los bancos, de Domino's Pizza, de Johnson & Johnson, ASML y JB Hunt. Después habla de unas inversiones estrategicas y de una fusion de las madereras. Finalmente da un pequeño crypto update donde habla de la confiscada mas grande en la historia y el error de dedo mas espectacular antes de contestar a unas preguntas de los Emprendeduros. ¡Síguenos en Instagram! Rodrigo: https://www.instagram.com/rodnavarro Emprendeduros: https://www.instagram.com/losemprendeduros Para mas información sobre nuestro fondo visita: https://emprendedurosventures.com/

United Kingdom correspondent Lucy Thomson spoke to Lisa Owen about the boss of MI5 intervening in a row over the collapse of the alleged Chinese spy case, as well as Johnson & Johnson facing legal action from thousands of people in the UK.

Johnson & Johnson reported its latest earnings and announced a separation of its orthopedics business into a standalone company. CEO Joaquin Duato discusses the company's next era, new warning labels for its multiple myeloma treatment Carvykti, and the future of J&J's consumer. Then, it's publication day for Andrew Ross Sorkin's new book 1929, which details the stock market crash that reshaped American capitalism. Plus, China sanctions a South Korean shipbuilder accused of aiding the U.S., and President Trump weighs in on a two-state solution and rebuilding Gaza. Joaquin Duato - 10:25 In this episode:Joe Kernen, @JoeSquawk Becky Quick, @BeckyQuickAndrew Ross Sorkin, @andrewrsorkinCameron Costa, @CameronCostaNY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carl Quintanilla, Jim Cramer and David Faber discussed stock markets down sharply after Monday's rebound rally — as trade tensions between the U.S. and China re-escalate. The anchors also delved into big banks kicking off earnings season, including quarterly results from JPMorgan Chase, Wells Fargo, Goldman Sachs and Citigroup. BlackRock Chairman & CEO Larry Fink joined the show at Post 9 to talk about earnings as well as the investment landscape both globally and in the U.S. Also in focus: The latest on OpenAI, hear what Oracle's new CEOs and Broadcom CEO Hock Tan had to say about AI, Johnson & Johnson's upbeat quarterly results and outlook. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This episode covers: Cardiology This Week: A concise summary of recent studies Visceral adiposity: paradigm shift in HFpEF management Artificial Intelligence in echocardiography Milestones: ISIS-2 Host: Susanna Price Guests: Carlos Aguiar, Milton Packer, Rudolf de Boer Want to watch the episode? Go to: https://esc365.escardio.org/event/2175 Want to watch the extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Whether you've ever been a boss or have ever had a boss, you know how much those singular individuals can shape the workplace. According to studies, a good manager can increase employee engagement by as much as 70%. And, according to a survey by the American Psychological Association, a whopping 75% of employees report their boss as the worst and most stressful part of their jobs.  So, how do we know if we're being a good boss or a bad boss?  Do we just know, or should we be looking out for specific things?   Enter the incredible stories that focus on what good leaders can learn from bad bosses, featuring the author of the brand-new book, The Devil Emails at Midnight, Mita Mallick.   What to listen for: The importance of time in creating a healthier workplace culture Accountability - and how to hold others accountable, as well as check in with yourself What boss archetypes Mita has found most personally challenging  The keys to being a good boss  About our guest   Mita Mallick is a Wall Street Journal and USA Today best-selling author. She's on a mission to fix what's broken in our workplaces. She's a corporate change-maker with a track record of transforming businesses and has had an extensive career as a marketing and human resources executive. Mallick has brought her talent and expertise to companies like Unilever, Pfizer, AVON, Johnson & Johnson, Carta, and more. She's a highly sought-after speaker and business coach to start-up founders, executives, and CEOs of public companies. Her highly anticipated second book, "The Devil Emails at Midnight: What Good Leaders Can Learn from Bad Bosses," comes out September 30, 2025.    For more about the book or to purchase The Devil Emails at Midnight:  What Good Leaders Can Learn From Bad Bosses, click here:  https://www.amazon.com/dp/1394316488